[8-K] Kezar Life Sciences, Inc. Reports Material Event
Kezar Life Sciences reported it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The current report furnishes that press release as Exhibit 99.1 and incorporates it by reference. The filing also includes a Cover Page Interactive Data File as Exhibit 104.
The company states that the information furnished under Item 2.02, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated. No additional financial detail or analysis is included within this report.
Kezar Life Sciences ha comunicato di aver diffuso un comunicato stampa con i risultati finanziari per il trimestre fiscale chiuso al 30 giugno 2025. Il presente rapporto allega tale comunicato come Esibizione 99.1 e lo incorpora per riferimento. La documentazione presentata include inoltre un Cover Page Interactive Data File come Esibizione 104.
L'azienda precisa che le informazioni fornite ai sensi dell'Item 2.02, inclusa l'Esibizione 99.1, non sono considerate "filed" ai fini della Sezione 18 dell'Exchange Act e non sono incorporate per riferimento in altri documenti, salvo diversa indicazione espressa. In questo rapporto non sono inclusi ulteriori dettagli o analisi finanziarie.
Kezar Life Sciences inform贸 que emiti贸 un comunicado de prensa con sus resultados financieros correspondientes al trimestre fiscal cerrado el 30 de junio de 2025. Este informe adjunta dicho comunicado como Exhibici贸n 99.1 y lo incorpora por referencia. La presentaci贸n incluye adem谩s un Cover Page Interactive Data File como Exhibici贸n 104.
La compa帽铆a declara que la informaci贸n suministrada bajo el Item 2.02, incluida la Exhibici贸n 99.1, no se considera "filed" a efectos de la Secci贸n 18 del Exchange Act y no se incorpora por referencia en otros documentos salvo que se indique expresamente. Este informe no contiene detalles financieros ni an谩lisis adicionales.
Kezar Life Sciences電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 須岅硠 攵勱赴鞚� 鞛鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 氤� 氤搓碃靹滊姅 頃措嫻 氤措弰鞛愲毳� Exhibit 99.1搿� 鞝滉车頃橁碃 彀胳“搿� 韽暔頃╇媹雼�. 鞝滌稖靹滊鞐愲姅 霕愴暅 Cover Page Interactive Data File鞚� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟.
須岇偓電� Item 2.02鞐� 霐半澕 鞝滉车霅� 鞝曤炒(Exhibit 99.1 韽暔)臧� Exchange Act鞚� "Section 18" 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婌溂氅�, 氇呾嫓鞝侅溂搿� 雼Μ 鞏戈笁霅� 瓴届毎毳� 鞝滌櫢頃橁碃 雼るジ 鞝滌稖靹滊鞐� 彀胳“搿� 韽暔霅橃 鞎婋姅雼り碃 氇呾嫓頃╇媹雼�. 鞚� 氤搓碃靹滌棎電� 於旉皜鞝侅澑 鞛 靹鸽秬靷暛鞚措倶 攵勳劃鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Kezar Life Sciences a d茅clar茅 avoir publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025. Le pr茅sent rapport fournit ce communiqu茅 en tant que Exhibit 99.1 et l'incorpore par r茅f茅rence. Le d茅p么t comprend 茅galement un Cover Page Interactive Data File en tant qu'Exhibit 104.
La soci茅t茅 indique que les informations fournies en vertu de l'Item 2.02, y compris l'Exhibit 99.1, ne sont pas consid茅r茅es comme "filed" aux fins de la Section 18 de l'Exchange Act et ne sont pas incorpor茅es par r茅f茅rence dans d'autres d茅p么ts sauf indication expresse contraire. Aucune information financi猫re suppl茅mentaire ni analyse n'est incluse dans ce rapport.
Kezar Life Sciences gab bekannt, eine Pressemitteilung mit den Finanzergebnissen f眉r das zum 30. Juni 2025 endende Gesch盲ftsquartal ver枚ffentlicht zu haben. Dieser Bericht stellt diese Pressemitteilung als Exhibit 99.1 zur Verf眉gung und nimmt sie per Verweis auf. Die Einreichung enth盲lt au脽erdem eine Cover Page Interactive Data File als Exhibit 104.
Das Unternehmen erkl盲rt, dass die unter Item 2.02 bereitgestellten Informationen, einschlie脽lich Exhibit 99.1, f眉r Zwecke von Abschnitt 18 des Exchange Act nicht als "filed" gelten und, sofern nicht ausdr眉cklich anders angegeben, nicht durch Verweis in andere Einreichungen aufgenommen werden. In diesem Bericht sind keine zus盲tzlichen finanziellen Details oder Analysen enthalten.
- None.
- None.
Insights
TL;DR: This 8-K furnishes a press release announcing Q2 2025 results but does not provide the underlying financial figures in the filing itself.
The filing explicitly furnishes a press release as Exhibit 99.1 that announces the company's financial results for the quarter ended June 30, 2025, and includes an Inline XBRL cover page as Exhibit 104. The company states the press release is "furnished" and not "filed" under Section 18, limiting statutory liability for this report. Because the 8-K does not include the substantive financial tables or metrics within its text, investors must consult Exhibit 99.1 to review the actual results. Impact assessment: not impactful鈥攖he report signals a disclosure but does not by itself change financial transparency.
TL;DR: The report follows standard disclosure practice by furnishing a results press release and clarifying its "furnished" status under the Exchange Act.
The document formally furnishes the press release reporting quarterly results and attaches the Inline XBRL cover page. The explicit disclaimer that the furnished material is not "filed" under Section 18 is a routine legal distinction clarifying liability and incorporation by reference. From a governance and disclosure control perspective, the 8-K documents the communication but does not itself provide new operational or financial metrics. Impact assessment: not impactful鈥攑rocedural disclosure without material new data in the filing.
Kezar Life Sciences ha comunicato di aver diffuso un comunicato stampa con i risultati finanziari per il trimestre fiscale chiuso al 30 giugno 2025. Il presente rapporto allega tale comunicato come Esibizione 99.1 e lo incorpora per riferimento. La documentazione presentata include inoltre un Cover Page Interactive Data File come Esibizione 104.
L'azienda precisa che le informazioni fornite ai sensi dell'Item 2.02, inclusa l'Esibizione 99.1, non sono considerate "filed" ai fini della Sezione 18 dell'Exchange Act e non sono incorporate per riferimento in altri documenti, salvo diversa indicazione espressa. In questo rapporto non sono inclusi ulteriori dettagli o analisi finanziarie.
Kezar Life Sciences inform贸 que emiti贸 un comunicado de prensa con sus resultados financieros correspondientes al trimestre fiscal cerrado el 30 de junio de 2025. Este informe adjunta dicho comunicado como Exhibici贸n 99.1 y lo incorpora por referencia. La presentaci贸n incluye adem谩s un Cover Page Interactive Data File como Exhibici贸n 104.
La compa帽铆a declara que la informaci贸n suministrada bajo el Item 2.02, incluida la Exhibici贸n 99.1, no se considera "filed" a efectos de la Secci贸n 18 del Exchange Act y no se incorpora por referencia en otros documentos salvo que se indique expresamente. Este informe no contiene detalles financieros ni an谩lisis adicionales.
Kezar Life Sciences電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 須岅硠 攵勱赴鞚� 鞛鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 氤� 氤搓碃靹滊姅 頃措嫻 氤措弰鞛愲毳� Exhibit 99.1搿� 鞝滉车頃橁碃 彀胳“搿� 韽暔頃╇媹雼�. 鞝滌稖靹滊鞐愲姅 霕愴暅 Cover Page Interactive Data File鞚� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟.
須岇偓電� Item 2.02鞐� 霐半澕 鞝滉车霅� 鞝曤炒(Exhibit 99.1 韽暔)臧� Exchange Act鞚� "Section 18" 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婌溂氅�, 氇呾嫓鞝侅溂搿� 雼Μ 鞏戈笁霅� 瓴届毎毳� 鞝滌櫢頃橁碃 雼るジ 鞝滌稖靹滊鞐� 彀胳“搿� 韽暔霅橃 鞎婋姅雼り碃 氇呾嫓頃╇媹雼�. 鞚� 氤搓碃靹滌棎電� 於旉皜鞝侅澑 鞛 靹鸽秬靷暛鞚措倶 攵勳劃鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Kezar Life Sciences a d茅clar茅 avoir publi茅 un communiqu茅 de presse pr茅sentant ses r茅sultats financiers pour le trimestre clos le 30 juin 2025. Le pr茅sent rapport fournit ce communiqu茅 en tant que Exhibit 99.1 et l'incorpore par r茅f茅rence. Le d茅p么t comprend 茅galement un Cover Page Interactive Data File en tant qu'Exhibit 104.
La soci茅t茅 indique que les informations fournies en vertu de l'Item 2.02, y compris l'Exhibit 99.1, ne sont pas consid茅r茅es comme "filed" aux fins de la Section 18 de l'Exchange Act et ne sont pas incorpor茅es par r茅f茅rence dans d'autres d茅p么ts sauf indication expresse contraire. Aucune information financi猫re suppl茅mentaire ni analyse n'est incluse dans ce rapport.
Kezar Life Sciences gab bekannt, eine Pressemitteilung mit den Finanzergebnissen f眉r das zum 30. Juni 2025 endende Gesch盲ftsquartal ver枚ffentlicht zu haben. Dieser Bericht stellt diese Pressemitteilung als Exhibit 99.1 zur Verf眉gung und nimmt sie per Verweis auf. Die Einreichung enth盲lt au脽erdem eine Cover Page Interactive Data File als Exhibit 104.
Das Unternehmen erkl盲rt, dass die unter Item 2.02 bereitgestellten Informationen, einschlie脽lich Exhibit 99.1, f眉r Zwecke von Abschnitt 18 des Exchange Act nicht als "filed" gelten und, sofern nicht ausdr眉cklich anders angegeben, nicht durch Verweis in andere Einreichungen aufgenommen werden. In diesem Bericht sind keine zus盲tzlichen finanziellen Details oder Analysen enthalten.
FAQ
What did Kezar Life Sciences (KZR) disclose in this 8-K?
Is the press release in the 8-K considered "filed" with the SEC?
Where can I find the actual financial figures referred to in this 8-K?
Does this 8-K include financial statements or detailed tables?
Does the filing state whether Kezar is an emerging growth company?
